Descripción de la empresa
Vor Biopharma Inc. operates as a clinical-stage enterprise dedicated to cell and genome engineering, specifically focusing on the development of novel therapies for hematologic malignancies. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player in the pursuit of advanced treatments for acute myeloid leukemia and other blood cancers. Currently, the organization employs a workforce of 76 individuals and holds a total market capitalization of $769.10 million. However, specific annual revenue figures are not disclosed in the available data, which limits the ability to calculate a revenue-based market share or operational scale relative to peers. The valuation metrics suggest that the market places a significant premium on the company's intellectual property and pipeline potential, as the market cap of $769.10 million vastly exceeds the tangible asset base, a common characteristic for clinical-stage biotechnology firms where value is derived from future clinical outcomes rather than current cash flows.
Salud financiera
The financial statements reveal a Net Income of $-695,980,992 for the trailing twelve months, while EBITDA stands at $-339,048,992, indicating a substantial operational burn rate. The gap between the reported revenue, which is listed as N/A, and the massive net income loss highlights a cost structure dominated by research and development expenditures and clinical trial costs typical of early-stage development. Free Cash Flow is reported at $-180,674,000, which signifies that the company is consuming its cash reserves to fund operations and development activities rather than generating surplus liquidity for distribution or debt repayment. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated commercial sales sufficient to establish traditional profitability ratios. The balance sheet shows a Cash position of $455.21 million against a total Debt of $3.00 million, demonstrating an overwhelmingly conservative capital structure with negligible leverage. Although the Debt to Equity ratio is listed as N/A due to the lack of equity data in the provided metrics, the disparity between cash and debt confirms the company is not burdened by significant interest obligations. Furthermore, the Current Ratio is an exceptionally high 18.20, indicating robust short-term liquidity and the ability to cover current liabilities many times over without immediate distress. Return on Equity and Return on Assets are both N/A or negative, with ROA specifically at -70.4%, revealing that for every dollar of assets, the company is currently generating a negative return due to heavy investment phases rather than income generation.
Evaluación de valoración
The Trailing Twelve Months P/E Ratio is N/A, while the Forward P/E is listed at -3.63, a negative figure that implies the company is not yet profitable and that future earnings estimates are insufficient to generate a traditional multiple based on current stock pricing. The Price to Book ratio is -1.94, which indicates that the market values the company at a negative multiple relative to its book value, a valuation metric that often appears in biotech portfolios where intangible assets outweigh recorded liabilities. The Price to Sales ratio is N/A, and the EV/EBITDA stands at -0.94, suggesting that alternative valuation methods also reflect the current lack of positive earnings power and the reliance on asset-light or pipeline-driven valuations. The stock has exhibited extreme volatility, with a 52-Week High of $65.80 and a 52-Week Low of $2.62, showing a price range that spans more than twenty-four times between the peak and trough. Given the 52-Week Low of $2.62 and the high of $65.80, the current trading price context is heavily influenced by the forward P/E of -3.63, suggesting the market is pricing in significant uncertainty regarding future commercialization timelines. The Beta value is 1.92, meaning the stock is expected to be nearly twice as volatile as the broader market, exposing investors to amplified price swings during periods of sector rotation or macroeconomic shifts.
Growth & Income
Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both listed as N/A, which precludes any comparative analysis of growth rates between sales and earnings as no baseline commercial revenue exists to establish a trend. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that all available capital is retained within the organization to finance ongoing research and development efforts rather than being distributed to shareholders. The absence of a dividend yield confirms that the company follows a growth strategy where earnings are reinvested into the pipeline, although the current Net Income remains negative. Consequently, the overall growth and income profile for Vor Biopharma Inc. is defined entirely by the potential future value of its clinical-stage assets and the successful execution of its genome-editing platform, rather than current cash generation or income distribution capabilities.